PurityPaulOR said:Relative and absolute effects need reading together.
I read this differently from PurityPaulOR, on substance rather than tone. Small molecule does not automatically mean cheap. Price is set by what the market will bear and by patent life, not by cost of goods, and I would not assume the savings reach patients.
One concrete data point for the thread. A quick sanity check on any figure quoted here: is it mean or median, is it intention-to-treat or completers, and what was the comparator. Three questions, and they resolve most disagreements in these threads.
Correct me if the detail matters more than I have assumed.
LabKate said:Small molecule does not automatically mean cheap.
There is a second half to this that has not been said yet. The gap between trial results and real-world results is consistent and it is not fraud. Trial participants get titration by protocol, scheduled contact, free drug and dietetic support; removing that infrastructure costs a few percentage points every time it has been measured. When your own curve sits below the published mean, that is the likeliest explanation before anything about you or your material.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsA narrower follow-up, since the general answer is now clear:
How to read a result like this without either dismissing it or over-reading it, since the summaries all read like press releases?
Reporting back.
Update — my curve sits below the published mean and the explanation is that the trial arm had support I do not have. That was reassuring rather than otherwise.